Work

Abstract CT133: A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer with PD-L1 expression

Year: 2018

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2018-ct133

Institutions: Sichuan University, West China Hospital of Sichuan University, State Key Laboratory of Biotherapy, Albert Einstein College of Medicine, Jacobi Medical Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2885702195

Cites:

Cited by: 9

Related to: 10